| |
 |
SmithKline Beecham p.l.c. Patents |
|
Assignee: SmithKline Beecham p.l.c.
Address: Brentford, GB
No. of patents: 455
Patents:
| Patent Number |
Title Of Patent |
Date Issued |
| RE39128 |
Pleuromutilin derivatives as antimicrobials |
June 13, 2006 |
| The present invention relates to pleuromutilin derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medical therapy, particularly antibacterial therapy. |
| D493518 |
Capsule link |
July 27, 2004 |
|
| D450585 |
Cap |
November 20, 2001 |
|
| D411108 |
Bottle |
June 15, 1999 |
|
| D410390 |
Bottle |
June 1, 1999 |
|
| D405879 |
Pharmaceutical tablet |
February 16, 1999 |
|
| D404309 |
Bottle |
January 19, 1999 |
|
| D399735 |
Bottle |
October 20, 1998 |
|
| D388959 |
Toothbrush handle |
January 13, 1998 |
|
| D384893 |
Bottle |
October 14, 1997 |
|
| D379307 |
Combined bottle and cap |
May 20, 1997 |
|
| D376643 |
Pharmaceutical tablet |
December 17, 1996 |
|
| D361615 |
Pharmaceutical tablet |
August 22, 1995 |
|
| D350821 |
Oral inhaler |
September 20, 1994 |
|
| D347996 |
Bottle |
June 21, 1994 |
|
| 7452906 |
Pyridine derivatives as Raf kinase inhibitors |
November 18, 2008 |
| Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy. |
| 7446106 |
Pyridylfurans and pyrroles as Raf kinase inhibitors |
November 4, 2008 |
| Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy. |
| 7432270 |
N-aroyl cyclic amines |
October 7, 2008 |
| This invention relates to N-aroyl cyclic amine derivatives and their use as orexin antagonists ##STR00001## wherein: Y represents a bond, oxygen, or a group (CH.sub.2).sub.n, wherein n represents 1, 2 or 3; m represents 1, 2, or 3; p represents ) or 1; X is NR, wherein R is H or (C. |
| 7429579 |
Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic a |
September 30, 2008 |
| The invention provides compounds of formula (I): wherein: R.sup.2 and R.sup.3 independently represent various substituents; R.sup.1 and R.sup.4 independently represent H, F, Cl, Br, C.sub.1-2alkyl, C.sub.1alkoxy, OH, CN, or NO.sub.2; B represents a sulfur atom or a --CH.sub.2-group; t |
| 7423052 |
Piperidine compounds for use as orexin receptor antagoinst |
September 9, 2008 |
| A invention relates to N aroyl cyclic amine derivatives and their use as pharmaceuticals, specifically as orexin receptor antagonists. |
| 7416853 |
Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and |
August 26, 2008 |
| The enzyme Lp-PLA.sub.2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA.sub.2, the use of an inhibitor of the enzyme Lp-PLA.sub.2 in therapy and a method of screening compounds to identify those compounds. |
| 7405217 |
N-aroyl piperazine derivatives as orexin receptor antagonists |
July 29, 2008 |
| This invention relates to N-aroyl cyclic amino derivatives and their use as pharmaceuticals. |
| 7405209 |
Protease inhibitors |
July 29, 2008 |
| The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and metho |
| 7399837 |
Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
July 15, 2008 |
| Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided. |
| 7375105 |
Pyridine substituted furan derivatives as Raf kinase inhibitors |
May 20, 2008 |
| Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy. Wherein X is O, CH.sub.2 CO, S or NH, or the moiety X--R.sup.1 is hydrogen; Y.sub.1 |
| 7368574 |
Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use |
May 6, 2008 |
| A hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione- , maleic acid salt., characterized in that it: (i) comprises water in the range of from 0.3 to 0.6 molar equivalents; and (ii) provides an infra red spectrum containing peaks at 1757, 1331, 1290, 1 |
| 7365077 |
Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor |
April 29, 2008 |
| ##STR00001## Disclosed are piperazine bis-amide derivatives useful as antagonists of the orexin receptor and pharmaceutical compositions containing the same. |
| 7358366 |
Thiazolidinedione derivative and its use as antidiabetic |
April 15, 2008 |
| A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione- , maleic acid salt (the "Polymorph") characterised in that it provides: (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602 cm.sup.-1; and/or (ii) a Raman spectrum |
| 7351832 |
Process for the preparation of thiazolidinedione derivatives |
April 1, 2008 |
| A process for preparing a compound of formula (I): ##STR00001## or a tautomeric form thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group; R.sup |
| 7344869 |
Isolated DNA comprising one or more genes specific for 5S clavam biosynthesis, vectors comprisin |
March 18, 2008 |
| Novel bacterial genes, microorganisms and processes for improving the manufacture of 5R clavams, eg. clavulanic acid. |
| 7297693 |
Nitrogen-containing heterocyclic compounds and their use as Raf inhibitors |
November 20, 2007 |
| Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy. |
| 7291740 |
5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione Mesylate salt |
November 6, 2007 |
| Disclosed are 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salts, or solvates thereof; processes for preparing such compounds, compositions comprising such compounds and the use of such compounds in medicine. |
| 7285557 |
Pyrimidinones as melanin concentrating hormone receptor 1 |
October 23, 2007 |
| A compound of formula (Ia) comprising a pharmaceutically acceptable salt or solvate thereof, formulations, processes of preparing, and methods of administering to mammals are provided ##STR00001## |
| 7282500 |
Imidazole-2-carboxamide derivatives as Raf kinase inhibitors |
October 16, 2007 |
| The present invention relates to compounds of formula (I): ##STR00001## or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, use as Raf Kinase Inhibitors and treatment methods for neurotraumatic diseases and cancer. |
| 7279152 |
Use of polyphosphate as a tooth erosion inhibitors in acidic compositions |
October 9, 2007 |
| The use of polyphosphate in acidic oral compositions, especially acid beverages with a pH between 2.2 and 5.5, to alleviate or prevent the tooth damage associated with the consumption of acid. The invention may be practiced using polyphosphate alone or in combination with calcium and |
| 7276229 |
Oral compositions comprising a viscosity modifier for reduction of tooth erosion |
October 2, 2007 |
| The use of viscosity modifying polymer materials, commonly used as stabilisers, thickeners and emulsifiers, as tooth erosion inhibitors in acidic compositions for oral administration, especially in acidic beverages such as fruit drinks and oral healthcare products such as mouthwashes |
| 7270962 |
Method of identifying modulators of nogo-functions |
September 18, 2007 |
| A method of identifying a modulator Nogo function, the method comprising: (i) providing (a) a BACE polypeptide; (b) a Nogo polypeptide; (c) a test agent under conditions that would permit binding of a BACE polypeptide (a) to a Nogo polypeptide (b) in the absence of the test agent ( |
| 7241579 |
Method of screening for GPR40 ligands |
July 10, 2007 |
| Methods of screening for ligands of the GPR40 receptor are provided, including methods utilizing fatty acid GPR40 ligands. |
| 7235658 |
Imidazol derivatives as Raf kinase inhibitors |
June 26, 2007 |
| Compounds of formula (I): ##STR00001## wherein X is O, CH.sub.2, S or NH, or the moiety X--R.sup.1 is hydrogen; V is CH or N; R.sup.1 is hydrogen, C.sub.1-6alkyl, C.sub.3-7cycloalkyl, aryl, arylC.sub.1-6alkyl, heterocyclyl, heterocyclylC.sub.1-6alkyl, heteroaryl, or heteroarylC.su |
| 7230109 |
5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hy |
June 12, 2007 |
| A hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione- , maleic acid salt, characterized in that it: (i) comprises water in the range of from 0.4 to 2.5% w/w; and (ii) provides an infra red spectrum containing peaks at 1749, 1703, 1645, 1623, 1365 and |
| 7229640 |
Paroxetine controlled release compositions |
June 12, 2007 |
| A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxtine. |
| 7220777 |
Lactam derivatives as antagonists for human 11cby receptors |
May 22, 2007 |
| The invention provides compounds of formula (I) ##STR00001## a salt, or solvate thereof. |
| 7217535 |
Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and |
May 15, 2007 |
| The enzyme Lp-PLA.sub.2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA.sub.2, the use of an inhibitor of the enzyme Lp-PLA.sub.2 in therapy and a method of screening compounds to identify those compounds. |
| 7214389 |
Process |
May 8, 2007 |
| A wet granulation process in which a pharmaceutical substance is granulated using a granulating fluid which is a halogenated hydrocarbon which has a normal boiling point below ambient temperature, for example 1,1,1,2-tetraflouroethane, under a pressure sufficient to maintain the halo |
| 7205408 |
Quinolines and nitrogenated derivative thereof substituted in 4-position by a piperidine-contain |
April 17, 2007 |
| Piperidine derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man. ##STR00001## |
| 7199137 |
Imidazole derivatives as Raf kinase inhibitors |
April 3, 2007 |
| Novel compounds (I) and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy wherein Ar is a group of formula a) or b). |
| 7186730 |
Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials |
March 6, 2007 |
| Piperidine derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly man. |
| 7169924 |
Pyrimidinone derivatives and their use in the treatment of atherosclerosis |
January 30, 2007 |
| Compound of formula (I): ##STR00001## are disclosed in which: R.sup.1 is an aryl group, optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C.sub.(1-6)alkyl, C.sub.(1-6)alkoxy, C.sub.(1-6)alkylthio, hydroxy, halogen, CN, and mono to |
| 7166608 |
N-aroyl piperazine derivatives as orexin receptor antagonists |
January 23, 2007 |
| This invention relates to N-aroyl piperazine derivatives of formula (I), wherein: Y represents NR.sup.2; m represents 1, 2 or 3; p represents 0 or 1; X is O, S, C.dbd.O, SO.sub.2, or CH.dbd.CH--; Ar.sup.1 is aryl, or a mono or bicyclic heteroaryl group containing up to 4 heteroatoms sele |
| 7163693 |
Multi-component pharmaceutical dosage form |
January 16, 2007 |
| A multi-component pharmaceutical dosage form comprising a plurality of drug substance-containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled |
|
|
|
